Teshale Teklue , Yuan Sun , Abid Muhammad , Yuzi Luo , Hua‐Ji Qiu

Transbound Emerg Dis. 2019 Sep 20. doi: 10.1111/tbed.13364

Abstract

African swine fever (ASF) is a highly lethal hemorrhagic disease of swine caused by African swine fever virus (ASFV), a unique and genetically complex virus. The disease continues to be a huge burden to the pig industry in Africa, Europe and recently in Asia, especially China. The purpose of this review is to recapitulate the current scenarios and evolving trends in ASF vaccine development. The unavailability of an applicable ASF vaccine is partly due to the complex nature of the virus, which encodes various proteins associated with immune evasion. Moreover, the incomplete understanding of immune protection determinants of ASFV hampers the rational vaccine design. Developing an effective ASF vaccine continues to be a challenging task due to many undefined features of ASFV immunobiology. Recent attempts on DNA and live attenuated ASF vaccines have been reported with promising efficacy, and especially live attenuated vaccines have been proved to provide complete homologous protection. Single-cycle viral vaccines have been developed for various diseases such as Rift Valley fever, bluetongue and the rational extension of these strategies could be helpful for developing single-cycle ASF vaccines. Therefore, live attenuated vaccines in short-term and single-cycle vaccines in long-term would be the next-generation of ASF vaccines.

© 2019 Blackwell Verlag GmbH.

KEYWORDS:

African swine fever; immune evasion; immune protection; vaccines